Matthias Mann

USPTO Granted Patents = 12 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 48(Granted Patents)

Location History:

Odense M, DK (2011 - 2014)
Munich, DE (2022)
Stockdorf, DE (2014 - 2023)

Company Filing History:

11 out of 1,289

Max-planck-gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

2 out of 915

The University of Chicago

patents

2 out of 132

Technische Universitat Munchen

Der Wissenschaft En E.v.

patent

7. 1 out of 832,812

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12173042 - Methods of treating cancers with CT45 targeted therapies (2024-12-24),

2. 11753437 - Peptide purification using mixed-phase solid phase extraction material (2023-09-12),

3. 11471532 - Methods for treatment ofinfections (2022-10-18),

4. 11355330 - Uses of isobaric tags in mass spectrometry (2022-06-07),

5. 11261223 - Methods of treating cancers with CT45 targeted therapies (2022-03-01),

6. 10828358 - vaccines (2020-11-10),

7. 9891194 - Acquisition of fragment ion mass spectra of ions separated by their mobility (2018-02-13),

8. 9791355 - Reaction vessel for sample preparation (2017-10-17),

9. 9063149 - Quantitative standard for mass spectrometry of proteins (2015-06-23),

10. 8741556 - Method for quantifying biomolecules (2014-06-03),

11. 8680239 - Use of RGM and its modulators (2014-03-25),

12. 7981420 - Therapeutic use of antibodies directed against repulsive guidance molecule (RGM) (2011-07-19),

Title: Matthias Mann: Innovator in Cancer Treatment and Peptide Purification

Introduction

Matthias Mann is a prominent inventor based in Stockdorf, Germany. He has made significant contributions to the fields of cancer treatment and peptide purification, holding a total of 12 patents. His innovative work focuses on targeted therapies and advanced purification methods that have the potential to revolutionize medical treatments.

Latest Patents

One of Mann's latest patents is titled "Methods of treating cancers with CT45 targeted therapies." This patent relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. The expressed antigen may be utilized in immunotherapeutic methods for the treatment of ovarian cancer. Aspects of this disclosure involve immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Another significant patent is "Peptide purification using mixed-phase solid phase extraction material." This invention describes a method for purifying peptides and/or polypeptides. The method includes loading a sample comprising peptides and/or polypeptides under acidic or neutral aqueous conditions on mixed-phase solid phase extraction (SPE) material. The process involves washing the SPE material with specific compositions and eluting the peptides and/or polypeptides with an alkaline composition.

Career Highlights

Matthias Mann has worked with esteemed organizations such as the Max Planck Society for the Advancement of Science and the University of Chicago. His experience in these institutions has contributed to his expertise in the fields of cancer research and peptide technology.

Collaborations

Throughout his career, Mann has collaborated with notable colleagues, including Felix Meissner and Bernhard K. Mueller. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Matthias Mann is a distinguished inventor whose work in cancer treatment and peptide purification has made a significant impact in the scientific community. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.